Publications
CER Interview with Dr. Kalipso Chalkidou
| Type: | Podcast |
| Date: | November 21, 2011 |
| Related Topics: | Aging Research, Drug Development, Drug Safety, Health, Medical Innovation, Policy, Research, Vision Loss |
Kalipso Chalkidou, MD, PhD, is the director of the policy consulting arm of NICE (National Institute for Health and Clinical Excellence), responsible for managing and developing consulting services for international clients drawing on the Institute’s experience of using evidence to inform health policy and practice. Between 2007 and 2008, she spent a year in the US as a Harkness fellow in health policy and practice, studying conditional coverage (Centre for Medical Technology Policy, San Francisco) and drug pricing policies (Department of Health Policy and Management, Johns Hopkins School of Public Health, Baltimore). She holds a doctorate on the molecular biology of prostate cancer from the University of Newcastle upon Tyne (2003).
Tweet
“The question is not whether you have perfectly personalized information, or whether you have less perfectly personalized information. The question is really whether you have some information or have no information. Right now, the alternative to CER is basically having very little or no information."
Tweet
This podcast series provides expert reactions to the CATT trial data in terms of what it will mean for wAMD patients and professionals, and its potential impact on future trials, policies and innovation.
To listen to interviews on this topic with other experts, click here.
To listen to interviews on this topic with other experts, click here.
Living Longer and Loving It!
Sign up for the Alliance's quarterly newsletter and get timely information on advancements in science, treatment, and health policy that help you "Live Longer and Love It."